Nkarta, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Nkarta, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$122.00M	-$128.19M	-$86.43M	-$51.51M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$104.08M	-$108.79M	-$86.08M	-$91.36M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.41	$-1.60	$-2.62	$-5.44
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.41	$-1.60	–	–

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$39.63M	$27.87M	$60.82M	$96.69M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$404.21M	$501.20M	$273.90M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$91.88M	$93.23M	$22.94M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$312.32M	$407.98M	$250.97M	–

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$88.70M	-$99.70M	-$67.93M	-$43.51M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.21M	$4.41M	$5.03M	$7.51M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$89.91M	-$104.11M	-$72.95M	-$51.02M

Peer Comparison

	You	Peer avg
P/E	–	11.6
Revenue Growth	–	+27.1%
ROE	-38.8%	-46.6%

PepGen Inc.–
Protalix BioTherapeutics, Inc.P/E 11.6(Yahoo)
Corbus Pharmaceuticals Holdings, Inc.–
Minerva Neurosciences, Inc.–